Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

PLoS Medicine

Volumn 13, Issue 12, 2016, Pages

  Lefebvre, Celine ^a   Bachelot, Thomas ^b   Filleron, Thomas ^c   Pedrero, Marion ^a   Campone, Mario ^d   Soria, Jean Charles ^a,e,f   Massard, Christophe ^e   Lévy, Christelle ^g   Arnedos, Monica ^e   Lacroix Triki, Magali ^a   Garrabey, Julie ^h   Boursin, Yannick ^e   Deloger, Marc ^e   Fu, Yu ^a   Commo, Frédéric ^a   Scott, Véronique ^a   Lacroix, Ludovic ^a,e   Dieci, Maria Vittoria ^i,j   Kamal, Maud ^k   Diéras, Véronique ^k   Gonçalves, Anthony ^l   Ferrerro, Jean Marc ^m   Romieu, Gilles ⁿ   Vanlemmens, Laurence ^o   Mouret Reynier, Marie Ange ^p   Théry, Jean Christophe ^q   Le Du, Fanny ^r   Guiu, Séverine ^s   Dalenc, Florence ^c   Clapisson, Gilles ^b   Bonnefoi, Hervé ^t   Jimenez, Marta ^h   Le Tourneau, Christophe ^k,u   André, Fabrice ^a,e,f   more..

^a Universite Paris Sud   (France)

^b CENTRE LÉON BÉRARD   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d UMR INSERM U892 CNRS 6299   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g CENTRE FRANÇOIS BACLESSE   (France)

^h R D Unicancer   (France)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^k INSTITUT CURIE   (France)

^l INSTITUT PAOLI CALMETTES   (France)

^m CENTRE ANTOINE LACASSAGNE   (France)

ⁿ CENTRE VAL D AURELLE   (France)

^o CENTRE OSCAR LAMBRET   (France)

^p CENTRE JEAN PERRIN   (France)

^q CENTRE HENRI BECQUEREL   (France)

^r CENTRE EUGÈNE MARQUIS   (France)

^s CENTRE GEORGES FRANÇOIS LECLERC   (France)

^t UNIVERSITÉ DE BORDEAUX   (France)

^u LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ALGORITHM; ARTICLE; BIOINFORMATICS; BONE METASTASIS; BREAST CANCER; CONTROLLED STUDY; FEMALE; FREQUENCY ANALYSIS; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; MUTAGENESIS; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; POINT MUTATION; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; SOMATIC MUTATION; TRANSLATIONAL RESEARCH; UNIVARIATE ANALYSIS; BREAST TUMOR; DNA SEQUENCE; EXOME; GENETICS; METASTASIS; MUTATION; PATHOLOGY;

BREAST NEOPLASMS; EXOME; FEMALE; HUMANS; MUTATION; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 85007551444     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002201     Document Type: Article

References (33)

1. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353–60. PubMed Central PMCID: PMCPMC3383766. doi: 10.1038/nature1114322722193
2. The Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi: 10.1038/nature1141223000897
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR, Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013;3(1):246–59. PubMed Central PMCID: PMCPMC3588146. doi: 10.1016/j.celrep.2012.12.00823318258
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92. doi: 10.1056/NEJMoa111320522397650
5. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123(11):4918–22. PubMed Central PMCID: PMC3809798. doi: 10.1172/JCI7035424135135
6. Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15(3):267–74. doi: 10.1016/S1470-2045(13)70611-924508104
7. Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–34. doi: 10.1016/S1470-2045(15)00188-626342236
8. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol. 2009;27(2):182–9. PubMed Central PMCID: PMCPMC2663421. doi: 10.1038/nbt.152319182786
9. Li H, Durbin R, Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589–95. PubMed Central PMCID: PMC2828108. doi: 10.1093/bioinformatics/btp69820080505
10. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303. PubMed Central PMCID: PMC2928508. doi: 10.1101/gr.107524.11020644199
11. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–9. PubMed Central PMCID: PMC3833702. doi: 10.1038/nbt.251423396013
12. Narzisi G, O'Rawe JA, Iossifov I, Fang H, Lee YH, Wang Z, et al. Accurate de novo and transmitted indel detection in exome-capture data using microassembly. Nat Methods. 2014;11(10):1033–6. PubMed Central PMCID: PMCPMC4180789. doi: 10.1038/nmeth.306925128977
13. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012;6(2):80–92. PubMed Central PMCID: PMC3679285. doi: 10.4161/fly.1969522728672
14. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805–11. doi: 10.1093/nar/gku107525355519
15. Favero F, Joshi T, Marquard AM, Birkbak NJ, Krzystanek M, Li Q, et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol. 2015;26(1):64–70. PubMed Central PMCID: PMCPMC4269342. doi: 10.1093/annonc/mdu47925319062
16. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30(5):413–21. PubMed Central PMCID: PMCPMC4383288. doi: 10.1038/nbt.220322544022
17. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–8. PubMed Central PMCID: PMCPMC3919509. doi: 10.1038/nature1221323770567
18. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 2012;22(8):1589–98. PubMed Central PMCID: PMCPMC3409272. doi: 10.1101/gr.134635.11122759861
19. Hua X, Xu H, Yang Y, Zhu J, Liu P, Lu Y, DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. Am J Hum Genet. 2013;93(3):439–51. PubMed Central PMCID: PMCPMC3769934. doi: 10.1016/j.ajhg.2013.07.00323954162
20. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G, GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41. PubMed Central PMCID: PMCPMC3218867. doi: 10.1186/gb-2011-12-4-r4121527027
21. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C, deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;17(1):31. PubMed Central PMCID: PMCPMC4762164.
22. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4(6):1116–30. PubMed Central PMCID: PMCPMC3881975. doi: 10.1016/j.celrep.2013.08.02224055055
23. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439–45. PubMed Central PMCID: PMCPMC3903423. doi: 10.1038/ng.282224185512
24. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446–51. PubMed Central PMCID: PMCPMC4009946. doi: 10.1038/ng.282324185510
25. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. Epub 2013/08/16. PubMed Central PMCID: PMCPmc3776390. doi: 10.1038/nature1247723945592
26. McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C, Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015;7(283):283ra54. PubMed Central PMCID: PMCPMC4636056. doi: 10.1126/scitranslmed.aaa140825877892
27. Orsetti B, Selves J, Bascoul-Mollevi C, Lasorsa L, Gordien K, Bibeau F, et al. Impact of chromosomal instability on colorectal cancer progression and outcome. BMC Cancer. 2014;14:121. PubMed Central PMCID: PMCPMC4233623. doi: 10.1186/1471-2407-14-12124559140
28. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R, ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12(10):573–83. doi: 10.1038/nrclinonc.2015.11726122181
29. Turner NC, Huang Bartlett C, Cristofanilli M, Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(17):1672–3.
30. Cybulski C, Kluzniak W, Huzarski T, Wokolorczyk D, Kashyap A, Jakubowska A, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015;16(6):638–44. doi: 10.1016/S1470-2045(15)70142-725959805
31. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. doi: 10.1056/NEJMoa110965322149876
32. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738–48. doi: 10.1056/NEJMoa160970927717303
33. Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol. 2016;27(2):256–62. doi: 10.1093/annonc/mdv54426578730